The University of North Carolina at Chapel Hill

Viiv Healthcare Company

Duke University

Glaxosmithkline Intellectual Property Development Limited

Macrogenics, Inc.

Janssen Sciences Ireland Unlimited Company

David Margolis

Leslie Sydnor Johnson

Barton F Haynes

Scott Koenig

Martha Alicia De La Rosa

Andrew Spaltenstein

Jun Tang

Liqin Liu

Chia-Ying Kao Lam

Guido Ferrari

Vincent Wing-Fai Tai

Jeffrey Lee Nordstrom

William R Spreen

Richard M Dunham

Julia A Sung

Herta Crauwels

Peter Williams

A method of treating HIV comprising intramuscular administration once every 4 weeks or less frequently of a combination of cabotegravir or a pharmaceutically acceptable salt thereof and rilpivirine or a pharmaceutically acceptable salt thereof, including the option of discontinuing administration of a first oral anti-retroviral regimen and intramuscularly administering, once four weeks or less often said combination of cabotegravir and rilpivirine.

Regimens for treating HIV infections and aids

The invention is directed to bispecific molecules comprising an HIV-1 envelope targeting arm and an arm targeting an effector cell, compositions comprising these bispecific molecule and methods of use. In certain aspects, the bispecific molecules of the present invention can bind to two different targets or epitopes on two different cells within the first epitope is expressed on a different cell type than the second epitope, such that the bispecific molecules can bring the two cells together. In certain aspects, the bispecific molecules of the present invention can bind to two different cells, wherein the bispecific molecules comprises an arm with the binding specificity of A32, 7B2, CH27, CH28 or CH44.

Bispecific molecules comprising an HIV-1 envelope targeting arm

Regimens for treating HIV infections and AIDS

The invention relates to compounds of Formula (I), salts thereof, combinations, pharmaceutical compositions thereof, as well as therapeutic methods of treatment and prevention.

Compounds useful in HIV therapy

The invention relates a compound of the formula: a pharmaceutically acceptable salt thereof, compositions thereof, and methods of therapeutic treatment using the same.

The invention is directed to bispecific molecules comprising an HIV-1 envelope targeting arm and an arm targeting an effector cell, compositions comprising these bispecific molecules and methods of use. In certain aspects, the bispecific molecules of the present invention can bind to two different targets or epitopes on two different cells wherein the first epitope is expressed on a different cell type than the second epitope, such that the bispecific molecules can bring the two cells together. In certain aspects, the bispecific molecules of the present invention can bind to two different cells, wherein the bispecific molecules comprises an arm with the binding specificity of A32, 7B2, CH27, CH28, or CH44.

Growing community of inventors

Chapel Hill, NC, United States of America

David Margolis